Abstract:OBJECTIVE:To evaluate the efficacy and safety of subcutaneous injection of recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma (RCC).METHODS:Forty-one patients with pathologically confirmed metastatic RCC after radical nephrectomy were enrolled into this study. Two or four consecutive cycles of subcutaneous injection of rhLL-2 were given, with each cycle duration of five weeks consisting of 4 weeks of treatment and one week of rest. The rhLL-2 was injected twice daily subcutaneously at a dose of 9 MIU on D1-D5 during week one, then 9 MIU twice daily on D1-D2 and followed by 9 MIU daily on D3-D5 during week 2-4. Patients were evaluated after the second cycle of treatment. If an objective response or stable disease was observed, the patient would receive another two cycles of treeatment.RESULTS:Of the 41 patients, the overall objective response rate was 17.1% (95% confidence interval, 5.6% to 28.6%) with a complete response (CR) rate of 0.0% and partial response rate (PR) of 17.1%. However, nineteen patients (46.3%) still had a stable disease (SD), and 15 (36.6%) had progressed disease (PD). The disease control rate was 63.4% and the median time to progression (mTTP) was 6 months. The 1-year survival rate was 71.2% with a median overall survival (mOS) rate of 22.5 months. Among 36 PP population, the overall objective response rate was 19.4% (95% confidence interval, 6.5% to 32.3%) with CR rate of 0.0% and PR rate of 19.4%. Sixteen patients(44.4%) had stable disease, and 13 (36.1%) progressed disease. The disease control rate was 63.9%. The 1-year survival rate was 66.7% with a median time to progression of 6 months. The median overall survival (mOS) had not reached yet. The follow-up data showed that the long term survival of the patient who responsed to the IL-2 therapy can be prolonged. Severe toxicity (> or = grade III) was rarely observed. Grade I or II toxicities such as fatigue (100.0%) and fever (82.9%) were frequently observed but reversible.CONCLUSION:Subcutaneous injection of recombinant human interleukin-2 may prolong the survival of patients with a metastatic renal cell carcinoma. This regimen is tolerable with rare severe toxicities.

Clinical Observation of Recombinant Human Interleukin-2 Administration to Tumor Region and Splanchnocoele

Activity of Recombinant Human Interleukin-15 Against Tumor Recurrence and Metastasis in Mice

THE AFFECION ON THE TREATMENT TO HEPATIC CANCER BY INJECTION OF CHEMICALS WITH IL-2 VIA EMBEDDED SUBCUTANEOUS CHEMATHERAPUTIC PUMP

The Clinical Study of the Change of HLA-DR, PFLMNF and Subtype of T Cell in Malignant Ascites and Hydrothorax Before and Post the Treatment of IL-2

Metaphase Ⅲ Study of Recombinant Human Interleukin-2 in the Treatment for Renal Cell Carcinoma with Lung Metastasis

Clinical Observation on Intrapleural Administration of Cisplatin and IL-2 Combined with Systemic Chemotherapy in the Treatment of Malignant Pleural Effusion of Lung Cancer

Therapeutic Effect of Tumor Infiltrating Lymphocyte Plus Interleukin-2 Intrapleural Injection on Advanced Cancer Patients with Malignant Pleural Effusion

A phase Ⅱ clinical trial of recombinant human interleukin-2 in treatment of advanced melanoma

Effect of Interleukin-2 and PDD in Treatment of Malignant Pleural Effu Sion

Clinical Observision of Intrapericardial Drug Through Intraducing the Intrapericardial Indwelling Tube in Patients with Malignant Pericardial Effusion

Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant effusion in children with solid tumors or lymphoma

Clinical Study on Serum and Tissue Levels of sIL-2R in Patients with G astric Cancer and Their Significance

INTERLEUKIN 2 ACTIVITY VARIATION OF MALIGNANT LYMPHOMA PATIENTS RECEIVING CHEMOTHERAPY

Interleukin-2 Administration Alters the Cd4(+)Foxp3(+) T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma

Clinical analysis javanica oil emulsion injection recombinant human interleukin-2 treatment of malignant pleural effusion

Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2)

Interleukin-2 Reverses CD8(+) T Cell Exhaustion in Clinical Malignant Pleural Effusion of Lung Cancer.

[Clinical Study on Recombinant Human Interleukin-2 (proleukin) in the Treatment of Metastatic Renal Cell Carcinoma].

Clinical Observation of Malignant Belly Cavity and Intrapleural Liquid Led out Through Retain Center Vein Pipe

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

Study on the TIL and NK of IL-2 Injected Via Pelvic Retroperitoneal Space in Gynecological Cancer Patient